ONCY Profile
Oncolytics Biotech Inc., headquartered in Calgary, Canada, is a biopharmaceutical company focused on advancing the development of innovative cancer treatments. Founded in 1998, the company operates in the developmental stage of pharmaceutical research, with a primary emphasis on discovering and progressing therapeutic products aimed at combatting various forms of cancer.
The cornerstone of Oncolytics Biotech's pipeline is pelareorep, an immunotherapeutic agent administered intravenously. Pelareorep is designed to target solid tumors and hematological malignancies, representing a promising approach in the field of cancer treatment. The company is actively engaged in advancing pelareorep through clinical trials, aiming to validate its efficacy and safety profile.
Oncolytics Biotech has strategically partnered with industry leaders such as Merck KGaA and Pfizer Inc. for the co-development of pelareorep. Collaborative efforts focus on exploring pelareorep's potential in combination therapies, particularly with paclitaxel and avelumab, a human anti-PD-L1 antibody. These partnerships underscore the company's commitment to leveraging synergistic approaches to enhance treatment outcomes for patients with hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer.
Beyond its core development activities, Oncolytics Biotech remains dedicated to expanding its portfolio through strategic alliances and ongoing research initiatives. With a steadfast dedication to innovation and improving patient outcomes in oncology, the company continues to advance towards its goal of bringing novel cancer therapies to market.
|
